Effect of levetiracetam on cognitive functions and quality of life: A one-year follow-up study

Epileptic Disorders

Volumn 10, Issue 4, 2008, Pages 297-305

  López Góngora, Mariana ^a   Martínez Domeño, Alejandro ^a   García, Carmen ^a   Escartín, Antonio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cognitive functions; Epilepsy; Levetiracetam; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADULT; AGED; AGGRESSIVENESS; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; COLIC; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GRAND MAL SEIZURE; HUMAN; INSOMNIA; IRRITABILITY; LONG TERM CARE; MALE; MONOTHERAPY; MOTOR PERFORMANCE; NEPHRITIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VERBAL BEHAVIOR; WORKING MEMORY;

ADULT; AGED; ANTICONVULSANTS; COGNITION; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIRACETAM; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEIZURES; YOUNG ADULT;

EID: 57049096031     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: 10.1684/epd.2008.0227     Document Type: Article

References (44)

1. Arroyo S. Eficacia y tolerabilidad de los nuevos antiepilépticos: posición del levetiracetam. Rev Neurol 2002; 35: 227-30.
2. Ben-Menachem E, Falter U. Efficacy and tolerability of Levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 1276-83.
3. Benton AL, Hamsher KdS. Multilingual Aphasia Examination: Manual of Instruction. Iowa City: AJA Associates, 1983.
4. Berg AT. Defining intractable epilepsy. Adv Neurol 2006; 97: 5-10.
5. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia 2006; 47: 431-6.
6. Betts T, Waegemans T, Crawford P. A multicenter, double-blind, randomized, parallel-group study to evaluate the tolerability and efficacy of two oral doses of Levetiracetam, 2000 mg daily and 4000 mg daily, without titration, in patients with refractory epilepsy. Seizure 2000; 9: 80-7.
7. Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006; 67: 400-6.
8. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
9. Ciesielski A, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: A comparative short-term study. Epilepsy Behav 2006; 9: 424-31.
10. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
11. Cramer J, Arrigo C, Van Hammee G, et al. Effect of Levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868-74.
12. Cramer J, Van Hammee G. The N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 2003; 4: 118-23.
13. Dodrill C, Arnett J, Hayers A, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999; 35: 109-21.
14. Estévez-González A. Stroop Test Software para DOS y PC-compatible. Departament de Psicologia. Institut Politècnic "Esteve Terrades i Illa". Barcelona: Cornellá, 1991.
15. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47: 77-90.
16. French JA. Refractory epilepsy: one size does not fit all. Epilepsy Curr 2006; 6: 177-80.
17. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005; 6: 373-81.
18. García-Sánchez C, Estévez-González A. CPT Software para DOS y PC-compatible. Departament de Psicologia. Institut Politècnic "Esteve Terrades i IIIa". Barcelona: Cornellá, 1991.
19. Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10: 486-94.
20. Herranz JL, Argumosa A. Características e indicaciones del Levetiracetam. Rev Neurol 2002; 35(Suppl. 1):110-6.
21. Johnson E, Jones J, Seidenberg M, et al. The relative impact of anxiety, depression and clinical seizure features on health-related quality of life in epilepsy. Epilepsia 2004; 45: 544-50.
22. Krakow K, Walker M, Otoul C, et al. Long-term continuation of Levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-4.
23. Lamberty Y, Klitgaard H. Lack of negative impact on cognitive function differentiates Levetiracetam (UCB L059) from other anti-epileptic drugs. Epilepsia 1998; 39 (Suppl. 6): 45; (2.053).
24. Lamberty Y, Margineau DG, Klitgaard H. Absence of negative impact of Levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav 2000; 1: 333-42.
25. Leach JP, Girvan J, Paul A, et al. Gabapentin and cognition: a double-blind, dose-ranging, placebo-controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997; 62: 372-6.
26. Lee TMC, Chan JKP. Factores que afectan el estado cognitivo de personas que sufren epilepsia. Rev Neurol 2002; 34: 861-5.
27. Lezak M. Neuropsychological Assessment. Third Edition. New York: Oxford University Press, 1995.
28. Malagón-Valdéz J. Efectos cognitivos de los fármacos antiepilépticos. Rev Neurol 2003; 36: 288-92.
29. Meador HJ, Gevins A, Loring DW, et al. Neuropsychological and neurophysiological effects of carbamazepine and levetiracetam. Neurology 2007; 69: 2076-84.
30. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999; 40: 1279-85.
31. Mecarelli O, Vicenzini E, Pulitano P, Accomero N. Clinical, cognitive and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine and levetiracetam in healthy volunteers. Ann Pharmacother 2004; 38: 1816-22.
32. Mitchell TN, Sander JW. Levetiracetam: a new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs Today 2001; 37: 665-73.
33. Motamedi G, Meador K. Epilepsy and Cognition. Epilepsy Behav 2003; 4: 525-38.
34. Neyens L, Alpherts W, Aldenkamp A. Cognitive effects of a new pyrrolidine derivate (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 411-9.
35. OECD 2007. Education at a glance, OECD briefing note for Spain. http://www.oecd.org/dataoecd/22/31/39317551.pdf [Search: 5 June 2008].
36. Piazzini A, Chifari R, Canevini MP, et al. R. Levetiracetam: An improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res 2006; 68: 181-8.
37. Salas-Puig J, Serratosa JM, Viteri C, et al. Seguridad del Levetiracetam como tratamiento adyuvante en la epilepsia: el estudio SKATE en España. Rev Neurol 2004; 38: 1117-22.
38. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of Levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-86.
39. Spreen O, Strauss E. A compendium of neuropsychological tests, second edition. New York: Oxford University Press, 1998.
40. Szaflarski J, Szaflarski M. Seizure disorders, depression and health-related quality of life. Epilepsy Behav 2004; 5: 50-7.
41. Torres X, Arroyo S, Araya S, et al. The Spanish version of the Quality-of-Life-in-Epilepsy Inventory (QOLIE - 31): Translation, Validity and reliability. Epilepsia 1999; 40: 1299-304.
42. Wechsler D. WAIS - III Escala de Inteligencia de Wechsler para Adultos - III. Manual de Aplicación y corrección. Segunda edición revisada. Madrid: TEA Ediciones, 2001.
43. Wilson B, Cockburn J, Baddeley A. The Rivermead Behavioral Memory Test. England, 1985. Thames Valley Test Company, 1991.
44. Zhou B, Zhang Q, Tian L, et al. Effects of levetiracetam as add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 2008; 12(2): 305-10.